T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.45B |
| 2 |
JPMorgan Chase
JPM
|
+$2.22B |
| 3 |
Atlassian
TEAM
|
+$2.08B |
| 4 |
NVIDIA
NVDA
|
+$1.81B |
| 5 |
Apple
AAPL
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.24B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.08B |
| 3 |
Microsoft
MSFT
|
+$2.68B |
| 4 |
Wells Fargo
WFC
|
+$1.93B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.86B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.79% |
| 2 | Healthcare | 17.2% |
| 3 | Consumer Discretionary | 15.17% |
| 4 | Financials | 10.75% |
| 5 | Communication Services | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RPTX
1126
DELISTED
Repare Therapeutics
RPTX
| $29.7M | ﹤0.01% |
2,088,345
-78,477
| -4% | -$1.16M |
|
1127
Cincinnati Financial
CINF
$26.5B
| $29.1M | ﹤0.01% |
213,681
-14,748
| -6% | -$1.81M |
|
|
BCPC
1128
Balchem Corp
BCPC
$5.65B
| $29M | ﹤0.01% |
212,375
+59,224
| +39% | +$8.48M |
|
1129
Ameresco
AMRC
$1.47B
| $28.9M | ﹤0.01% |
363,857
+5,829
| +2% | +$368K |
|
1130
Ingevity
NGVT
$2.62B
| $28.9M | ﹤0.01% |
450,912
-33,495
| -7% | -$2.24M |
|
1131
Pacira BioSciences
PCRX
$924M
| $28.8M | ﹤0.01% |
377,765
+2,304
| +0.6% | +$154K |
|
1132
Five Star Bancorp
FSBC
$1.16B
| $28.8M | ﹤0.01% |
1,017,272
+12,675
| +1% | +$382K |
|
1133
Best Buy
BBY
$18B
| $28.7M | ﹤0.01% |
315,826
-19,113
| -6% | -$1.89M |
|
1134
Kimbell Royalty Partners
KRP
$1.53B
| $28.6M | ﹤0.01% |
1,755,915
-444,770
| -20% | -$6.91M |
|
|
SPNS
1135
DELISTED
Sapiens International
SPNS
| $28.5M | ﹤0.01% |
1,123,376
+15,463
| +1% | +$450K |
|
1136
Omnicom Group
OMC
$23.5B
| $28.4M | ﹤0.01% |
334,745
-21,715
| -6% | -$1.75M |
|
1137
Krispy Kreme
DNUT
$569M
| $28.3M | ﹤0.01% |
+1,905,850
| New | +$28.6M |
|
1138
Axcelis
ACLS
$4.42B
| $28.1M | ﹤0.01% |
+371,381
| New | +$25.4M |
|
1139
Lyell Immunopharma
LYEL
$347M
| $27.7M | ﹤0.01% |
274,696
+17,631
| +7% | +$2.14M |
|
1140
Ranpak Holdings
PACK
$464M
| $27.7M | ﹤0.01% |
1,357,587
+3,886
| +0.3% | +$101K |
|
1141
Roku
ROKU
$22.9B
| $27.5M | ﹤0.01% |
219,763
-974,877
| -82% | -$143M |
|
1142
Teladoc Health
TDOC
$1.26B
| $27.4M | ﹤0.01% |
380,081
+18,182
| +5% | +$1.31M |
|
1143
Wabtec
WAB
$50.3B
| $27.4M | ﹤0.01% |
284,593
-7,791
| -3% | -$722K |
|
1144
Synchrony
SYF
$26.1B
| $27.3M | ﹤0.01% |
785,355
-43,208
| -5% | -$1.81M |
|
1145
Moog Inc Class A
MOG.A
$13.6B
| $27.3M | ﹤0.01% |
310,453
-57,414
| -16% | -$4.65M |
|
|
PVBC
1146
DELISTED
Provident Bancorp
PVBC
| $27.2M | ﹤0.01% |
1,677,586
+300
| +0% | +$5.1K |
|
1147
H.B. Fuller
FUL
$3.24B
| $27.1M | ﹤0.01% |
410,673
+22,304
| +6% | +$1.57M |
|
1148
CareDx
CDNA
$2.45B
| $27.1M | ﹤0.01% |
732,182
-116,631
| -14% | -$4.55M |
|
1149
Alector
ALEC
$228M
| $26.9M | ﹤0.01% |
1,890,908
+14,060
| +0.7% | +$222K |
|
|
MRO
1150
DELISTED
Marathon Oil Corporation
MRO
| $26.9M | ﹤0.01% |
1,071,057
-31,347
| -3% | -$673K |
|
Similar funds
T. Rowe Price Associates's Q1 2022 Portfolio in Review
As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
- T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
- T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
- T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
- T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
- T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.